Skip to content

Study · Randomized controlled trial · n = 40 · 1995

25 results

The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance.

Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W, Sharp P, Johnston DG

The Journal of clinical endocrinology and metabolism1 Feb 1995Cited by 99 (Europe PMC)

PMID7852490 (opens in a new tab)DOI10.1210/jcem.80.2.7852490 (opens in a new tab)PepBankPUB-07852490
Publisher pagePubMedAsk about this study
Jump to 25 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study25

25 results from studies that gave the peptide. 25 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hypopituitary adults, fasting plasma glucose was similar during GH and placebo administration.

    In plain wordsIn hypopituitary adults, fasting glucose was similar with GH and placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeControlled-phase fasting glucose
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the controlled phase, fasting plasma glucose was similar during GH and placebo administration, but fasting insulin and C-peptide increased during GH therapy, but not during placebo treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hypopituitary adults, glucose AUC increased significantly during 6 months of GH and exceeded placebo at 6 months.

    In plain wordsIn hypopituitary adults, glucose AUC increased during GH treatment and was higher than with placebo at 6 months.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseControlled-phase glucose AUC
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The mean area under the curve (AUC) for glucose increased by a small, but significant, extent over the 6 months of GH treatment and was higher at 6 months than during placebo treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  3. 03HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, HDL3 cholesterol did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, HDL3 cholesterol did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeHDL3 cholesterol
    Study

    n = 40

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  4. 04HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, apoprotein-A1 did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, apoprotein-A1 did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeApoprotein-A1
    Study

    n = 40

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  5. 05HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, apoprotein-B did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, apoprotein-B did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeApoprotein-B
    Study

    n = 40

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  6. 06HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting insulin increased during GH therapy but not during placebo treatment.

    In plain wordsIn hypopituitary adults, fasting insulin increased during GH treatment but not placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseControlled-phase fasting insulin
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the controlled phase, fasting plasma glucose was similar during GH and placebo administration, but fasting insulin and C-peptide increased during GH therapy, but not during placebo treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  7. 07HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting C-peptide increased during GH therapy but not during placebo treatment.

    In plain wordsIn hypopituitary adults, fasting C-peptide increased during GH treatment but not placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseControlled-phase fasting C-peptide
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the controlled phase, fasting plasma glucose was similar during GH and placebo administration, but fasting insulin and C-peptide increased during GH therapy, but not during placebo treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  8. 08HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, insulin AUC increased during GH treatment.

    In plain wordsIn hypopituitary adults, insulin AUC increased during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseControlled-phase insulin AUC
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The AUC for insulin also increased during GH treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  9. 09HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting triglycerides did not change at any stage of GH treatment.

    In plain wordsIn hypopituitary adults, fasting triglycerides did not change during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeFasting triglycerides
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no change in fasting triglyceride levels at any stage of the study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  10. 10HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting total cholesterol did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, total cholesterol did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeFasting total cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  11. 11HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting LDL cholesterol did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, LDL cholesterol did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeFasting LDL cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  12. 12HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, total HDL cholesterol did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, HDL cholesterol did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeTotal HDL cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  13. 13HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, HDL2 cholesterol did not change significantly during the placebo-controlled GH phase.

    In plain wordsIn hypopituitary adults, HDL2 cholesterol did not change significantly during GH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeHDL2 cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  14. 14HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, total cholesterol showed a sustained downward trend during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, total cholesterol showed a downward trend during open-phase GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseOpen-phase total cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    In the open phase of the trial, total and low density lipoprotein cholesterol showed a sustained downward trend during GH therapy.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  15. 15HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, LDL cholesterol showed a sustained downward trend during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, LDL cholesterol showed a downward trend during open-phase GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseOpen-phase LDL cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    In the open phase of the trial, total and low density lipoprotein cholesterol showed a sustained downward trend during GH therapy.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  16. 16HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, HDL cholesterol was significantly higher than pretreatment at 18 months of GH therapy.

    In plain wordsIn hypopituitary adults, HDL cholesterol increased from pretreatment during 18 months of GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHDL cholesterol at 18 months
    Study

    n: not reported in source

    Comparator
    Pretreatment levels
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Compared to the pretreatment level, the HDL cholesterol concentration was significantly higher at 18 months.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  17. 17HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, HDL2 cholesterol did not differ from pretreatment during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, HDL2 cholesterol did not change from pretreatment during open-phase GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOpen-phase HDL2 cholesterol
    Study

    n: not reported in source

    Comparator
    Pretreatment levels
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    Cholesterol subfractions HDL2 and HDL3 and apoprotein-A1 and -B were not different from the pretreatment levels.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  18. 18HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, HDL3 cholesterol did not differ from pretreatment during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, HDL3 cholesterol did not change from pretreatment during open-phase GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOpen-phase HDL3 cholesterol
    Study

    n: not reported in source

    Comparator
    Pretreatment levels
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    Cholesterol subfractions HDL2 and HDL3 and apoprotein-A1 and -B were not different from the pretreatment levels.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  19. 19HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, apoprotein-A1 did not differ from pretreatment during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, apoprotein-A1 did not change from pretreatment during open-phase GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOpen-phase apoprotein-A1
    Study

    n: not reported in source

    Comparator
    Pretreatment levels
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    Cholesterol subfractions HDL2 and HDL3 and apoprotein-A1 and -B were not different from the pretreatment levels.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  20. 20HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, apoprotein-B did not differ from pretreatment during open-phase GH therapy.

    In plain wordsIn hypopituitary adults, apoprotein-B did not change from pretreatment during open-phase GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOpen-phase apoprotein-B
    Study

    n: not reported in source

    Comparator
    Pretreatment levels
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg dailyAs given in this study (human).

    Source sentences

    Summary
    Cholesterol subfractions HDL2 and HDL3 and apoprotein-A1 and -B were not different from the pretreatment levels.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  21. 21HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, total/HDL cholesterol ratio decreased significantly at 12 and 18 months of GH therapy.

    In plain wordsIn hypopituitary adults, total/HDL cholesterol ratio decreased during GH therapy at 12 and 18 months.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTotal/HDL cholesterol ratio
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 12 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The total/HDL cholesterol ratio decreased significantly at 12 and 18 months.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  22. 22HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting glucose increased at 6 and 12 months of GH treatment during the open trial.

    In plain wordsIn hypopituitary adults, fasting glucose increased during GH treatment at 6 and 12 months in the open trial.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOpen-trial fasting glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    During the open trial, the fasting plasma glucose level increased at 6 and 12 months, and the fasting plasma insulin level increased at 6, 12, and 18 months of GH treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  23. 23HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, fasting insulin increased at 6, 12 and 18 months of GH treatment during the open trial.

    In plain wordsIn hypopituitary adults, fasting insulin increased during GH treatment at 6, 12 and 18 months in the open trial.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOpen-trial fasting insulin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6, 12 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    During the open trial, the fasting plasma glucose level increased at 6 and 12 months, and the fasting plasma insulin level increased at 6, 12, and 18 months of GH treatment.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  24. 24HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, glucose AUC was significantly higher at 6 months of GH therapy during the open trial.

    In plain wordsIn hypopituitary adults, glucose AUC increased during GH therapy at 6 months in the open trial.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOpen-trial glucose AUC
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The plasma glucose AUC during the oral glucose tolerance test was significantly higher at 6 months, and the plasma insulin AUC was significantly higher at 6, 12, and 18 months of GH therapy.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.
  25. 25HumanNon-randomized trialEfficacy outcome

    In hypopituitary adults, insulin AUC was significantly higher at 6, 12 and 18 months of GH therapy during the open trial.

    In plain wordsIn hypopituitary adults, insulin AUC increased during GH therapy at 6, 12 and 18 months in the open trial.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOpen-trial insulin AUC
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.04 +/- 0.01 IU/kg daily · 6, 12 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The plasma glucose AUC during the oral glucose tolerance test was significantly higher at 6 months, and the plasma insulin AUC was significantly higher at 6, 12, and 18 months of GH therapy.
    2 context sentences
    Summary · context
    The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial.
    Summary · context
    The daily GH dose was 0.04 +/- 0.01 IU/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.